Evidence map›Paper›PMID 26932552›Full record

ReviewCNS drugs2016

Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date.

Mary R Lee, Matthew C H Rohn, Gianluigi Tanda, Lorenzo Leggio

Open access · greenAbstract readReview
In one paragraph

Review in CNS drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
17.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Oxytocin Reduces Alcohol Cue-Reactivity in Alcohol-Dependent Rats and Humans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Trial
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Mary R LeeSection on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism, and National Institute on Drug Abuse, 10 Center Drive, MSC-1108, Bethesda, MD, 20892-1108, USA. leemary@mail.nih.gov.
Matthew C H RohnSection on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism, and National Institute on Drug Abuse, 10 Center Drive, MSC-1108, Bethesda, MD, 20892-1108, USA.
Gianluigi TandaMedication Development Program, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Baltimore, MD, USA.
Lorenzo LeggioSection on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism, and National Institute on Drug Abuse, 10 Center Drive, MSC-1108, Bethesda, MD, 20892-1108, USA.
National Institute on Drug Abuse · USNational Institute on Alcohol Abuse and Alcoholism · US

Funding

Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)ZIAAA000218 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI LEGGIO, LORENZO · 2013 to 2020
$22.8M
Investigation On The Behavior And Related Neuro-Electrochemistry Of Potential Medications For The Treatment Of Substance Use Disorders.ZIADA000611 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI TANDA, GIANLUIGI · 2016 to 2025
$16.0M
Intramural NIH HHS Z99 AA999999Intramural NIH HHS ZIA AA000218
6 · The paper itself

Abstract

The neuropeptide oxytocin plays a role in reward, stress, social affiliation, learning, and memory processes. As such, there is increasing interest in oxytocin as a potential treatment for addictions. The endogenous oxytocin system is itself altered by short- or long-term exposure to drugs of abuse. A large number of preclinical studies in rodents have investigated the effect of oxytocin administration on various drug-induced behaviors to determine whether oxytocin can reverse the neuroadaptations occurring with repeated drug and alcohol use. In addition, the mechanisms by which oxytocin acts to modify the behavioral response to drugs of abuse are beginning to be understood. More recently, a few small clinical studies have been conducted in cocaine, cannabis, and alcohol dependence. This review summarizes the preclinical as well as clinical literature to date on the oxytocin system and its relevance to drug and alcohol addiction.

Indexed as

AnimalsBehavior, AddictiveBrainCentral Nervous System AgentsHumansOxytocinSubstance-Related DisordersCentral Nervous System AgentsOxytocin

Identifiers

PMID26932552
PMCPMC4815424
OpenAlexW2289138162

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.